0.50 / AMA PRA Category 1 CreditTM 0.50 / CNE Contact Hours
Presented by the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing.
Supported by an educational grant from AstraZeneca.
Lung cancer is the worldwide leading cause of cancer-related mortality. The vast majority of these cases (about 85%) are characterized as non-small cell lung cancer (NSCLC). In recent years, NSCLC has been found to have a multidimensional typology and etiology driven by molecular changes in lung tissue. The knowledge that the molecular structure of tumor cells has been altered has led to the development of targeted biologic agents and, even more relevant in patients with lung cancer, moderation of the immune system itself via the intervention of novel checkpoint inhibitors. A number of new drugs, including nivolumab, pembrolizumab, and atezolizumab, have been introduced in the past several years as first- and second-line agents in patients with advanced and metastatic NSCLC. These drugs have revolutionized the treatment guidelines for the disease. Early in 2018, durvalumab was approved for treating patients with stage III disease following concurrent chemoradiation therapy, the aim of which is to prevent disease progression. This educational module will explore the biology of the immune system and the rationale for the development and use of checkpoint inhibitors in patients with stage III and advanced NSCLC. It will also address the importance of early identification and treatment of autoimmune adverse events and the role of biomarker testing. Finally, this activity will describe the clinical studies now underway and in recruitment, which are investigating the potential role of immune-checkpoint inhibitors in patients with NSCLC, particularly in the early phases of the disease.
This activity is intended for oncology physicians, physician assistants, nurse practitioners, nurses, and other healthcare providers who treat and manage patients with NSCLC. No prerequisites required.
After participating in this activity, the participant will demonstrate the ability to:
RECOGNIZE the need for interventions that can delay NSCLC progression, and the rationale for using immune-checkpoint inhibitors for this purpose.
EVALUATE recent literature on the use of ICIs in stage III and early NSCLC, and the implications of these findings for practice.
IMPLEMENT recently-approved immune-checkpoint inhibitors into treatment plans for nonresectable stage III NSCLC patients.
The Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing take responsibility for the content, quality, and scientific integrity of this CME/CNE activity.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing. The Johns Hopkins University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Contact Hour(s)
The Institute for Johns Hopkins Nursing is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This 0.50 contact hour educational activity is provided by the Institute for Johns Hopkins Nursing. Claim only those contact hours actually spent in the activity. Statements will be awarded for this educational activity until September 29, 2019.
Policy on Speaker and Provider Disclosure
It is the policy of the Johns Hopkins University School of Medicine and the Institute for Johns Hopkins Nursing that the speaker and provider globally disclose conflicts of interest. The Johns Hopkins University School of Medicine OCME has established policies that will identify and resolve conflicts of interest prior to this educational activity. Detailed disclosure will be made prior to presentation of the education.
Full Disclosure Policy Affecting CME Activities
As a provider approved by the Accreditation Council for Continuing Medical Education (ACCME), Johns Hopkins University School of Medicine Office of Continuing Medical Education (OCME) requires attested and signed global disclosure of the existence of all financial interests or relationships with commercial interest from any individual in a position to control the content of a CME activity sponsored by OCME.
The following relationships have been reported for this activity:
Dr. Ettinger reports serving as a principal investigator for Golden Biotechnology Corp and serving as a consultant for AbbVie Inc, BeyondSpring Pharmaceuticals, Inc, Boehringer Ingelheim Vetmedica, Inc, Bristol-Myers Squibb Company/Sanofi-Aventis US LLC, Eli Lilly and Company, Guardant Health Inc., and Genentech Inc.
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution that receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
Johns Hopkins University School of Medicine Chair and Planner David S. Ettinger, MD Alex Grass Professor of Oncology Sidney Kimmel Comprehensive Cancer Center Baltimore, Maryland
Participating Faculty Kristen Ashley Marrone, MD Assistant Professor of Oncology Upper Aerodigestive Disease Program Sidney Kimmel Comprehensive Cancer Center Assistant Program Director Medical Oncology Fellowship Program Johns Hopkins Hospital Oncology Center Baltimore, Maryland
Nurse Planner Rebecca Barshick, RN, MSN Nurse Educator The Institute for Johns Hopkins Nursing Baltimore, Maryland
Nurse Reviewer MiKaela Olsen APRN-CNS, MS, AOCNS, FAAN Oncology and Hematology Clinical Nurse Specialist Ambulatory Oncology Sidney Kimmel Comprehensive Cancer Center Johns Hopkins University School of Medicine Baltimore, Maryland
Peer Reviewer Susan L. Gearhart, MD Associate Professor of Surgery Johns Hopkins University School of Medicine Baltimore, Maryland
Off-Label Product Discussion
No author has indicated that he/she will reference unlabeled/unapproved uses of drugs or products.
Non-Endorsement of Products
The Institute for Johns Hopkins Nursing and the American Nurses Credentialing Center do not endorse the use of any commercial products discussed or displayed in conjunction with this educational activity.
The opinions and recommendations expressed by faculty and other experts whose input is included in this activity are their own. This activity is produced for educational purposes only. Use of Johns Hopkins University School of Medicine name implies review of educational format, design, and approach. Please review the complete prescribing information of specific drugs or combinations of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.
The following is an interactive case module designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited pre-test, an interactive case study, and a CME post-test and evaluation. All 3 sections must be completed to receive CME credit. A certificate of participation will be available online immediately following successful completion of the activity. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
For information about the accreditation of this program, please contact the CME Office 410-955-2959 or email email@example.com.
Confidentiality Disclaimer for CME Activity Participant
I certify that I am participating in this Johns Hopkins University School of Medicine activity for CME-accredited training and/or educational purposes.
I understand that while I am participating in this capacity, I may be exposed to "protected health information," as that term is defined and used in Hopkins policies and in the federal HIPAA privacy regulations (the “Privacy Regulations”). Protected health information is information about a person's health or treatment that identifies the person.
I pledge and agree to use and disclose any of this protected health information only for the training and/or educational purposes of my visit and to keep the information confidential. I agree not to post or discuss this protected health information, including pictures and/or videos, on any social media site (eg, Facebook, Twitter, etc.), in any electronic messaging program or through any portable electronic device.
I understand that I may direct to the Johns Hopkins Privacy Officer any questions I have about my obligations under this Confidentiality Pledge or under any of the Hopkins policies and procedures and applicable laws and regulations related to confidentiality. The contact information is: Johns Hopkins Privacy Officer, telephone: 410-735-6509, e-mail: HIPAA@jhmi.edu.
“The Office of Continuing Medical Education at the Johns Hopkins University School of Medicine, as sponsor of this activity, has relayed information with the CME attendees/participants and certify that the visitor is here for training, education and/or observation purposes only.”
For CME questions, please contact the CME Office 410-955-2959 or email firstname.lastname@example.org.
Johns Hopkins University School of Medicine Office of Continuing Medical Education 720 Rutland Avenue/ Turner 20 Baltimore, Maryland 21205-2195 Reviewed & Approved by: General Counsel, Johns Hopkins Medicine (4/1/03) (Updated 4/09 and 3/14)
THE INSTITUTE FOR JOHNS HOPKINS NURSING MISSION STATEMENT
The mission of the Institute for Johns Hopkins Nursing is to share the innovations of Johns Hopkins Nursing in practice, education, and research—locally, nationally, and globally. Our goal in continuing nursing education is to bring you activities that reflect the expertise and creativity of Johns Hopkins Nursing. Our service values are quality, integrity, flexibility, and personal attentiveness. We appreciate your thoughts and welcome your concerns—please feel free to e-mail us: IJHN@.jhmi.edu.
HARDWARE & SOFTWARE REQUIREMENTS
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.
Hardware and Software Requirements
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required